Screener
Vaxcyte, Inc. PCVX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accrued compensation | (15,018) | (14,418) |
| Accrued contract manufacturing expenses | 54,852 | 8,088 |
| Accrued expenses | (15,571) | (4,393) |
| Net cash used in operating activities | (280,625) | (166,274) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (2,107) | (5,424) |
| Purchases of manufacturing facility build-out and equipment construction-in-progress | (12,687) | (21,327) |
| Purchases of investments | (584,129) | (314,485) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Vaxcyte, Inc.'s operating cash flow?
- Vaxcyte, Inc. (PCVX) reported operating cash flow of -$280.63M in Q1 2026.
- How has Vaxcyte, Inc.'s operating cash flow changed year-over-year?
- Vaxcyte, Inc.'s operating cash flow decreased by 68.8% year-over-year, from -$166.27M to -$280.63M.
- What is the long-term trend for Vaxcyte, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Vaxcyte, Inc.'s operating cash flow has grown at a 52.4% compound annual growth rate (CAGR), from -$121.39M to -$655.58M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Vaxcyte, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude